17 Jun 2013
US Patent Granted Covering use of VEGFR-3
04 Jun 2013
VGX-100 Phase 1 Oncology Trial Presented at ASCO 2013
27 May 2013
Change of Director’s Interest Notice
24 May 2013
Open Briefing: VGX-300 Potential in AMD
23 May 2013
Change of Director’s Interest Notice
20 May 2013
Change of Director’s Interest Notice
17 May 2013
Progress of VGX-100 Phase 1 trial to be presented at ASCO
09 May 2013
VEGF-C shown to have major role in Age-Related Macular Degeneration (AMD)
08 Mar 2013
Circadian grants world-wide licence to Santa Cruz Biotechnology Inc
06 Mar 2013
Edison Research publishes updated analysis on Circadian. Values the company at $1.93/share
27 Feb 2013
Circadian commences worldwide marketing & sales of unique VEGF-C & VEGF-D products as research reagents
25 Feb 2013
Open Briefing: Interview with CEO & MD Robert Klupacs on H1 Results & Outlook
22 Feb 2013
Appointment of CFO and Company Secretary
20 Feb 2013
Resignation of CFO and Company Secretary
18 Feb 2013
Half Year Report & Accounts
07 Feb 2013
R&D Tax Incentive - Circadian Receives $1.3m
04 Feb 2013
VGX-100 Phase 1 Clinical Trial Program Update
10 Jan 2013
Company Presentation at JP Morgan Biotech Showcase
17 Dec 2012
Change of Director’s Interest Notice
11 Dec 2012
Open Briefing interview with MD & CEO Robert Klupacs
21 Nov 2012
Change of Director's Interest Notice
20 Nov 2012
Results of Annual General Meeting 20 November 2012
20 Nov 2012
CEO AGM Presentation to shareholders
20 Nov 2012
Chairman's Address to Shareholders
20 Nov 2012
CEO AGM Presentation to Shareholders
15 Nov 2012
Circadian grants world-wide licence to Bio-Rad to market research products
08 Nov 2012
VGX-100 Poster Presentation at EORTC
08 Nov 2012
VGX-100 Poster Presentation at EORTC
07 Nov 2012
VGX-100 Top 10 Oncology Candidate Windhover Conference
02 Nov 2012
AusBiotech Presentation Company Update
22 Oct 2012
Annual Report / Notice of AGM and Proxy
02 Oct 2012
Dr Errol Malta – Resignation as Director
24 Sep 2012
Open Briefing - FY2012 Results and Outlook
24 Aug 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
23 Aug 2012
Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012
17 Jul 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
12 Jul 2012
Change of Director’s Interest Notice
10 Jul 2012
Change of Director’s Interest Notice
09 Jul 2012
Alpha Securities Analyst Investment Research Report Available on Circadian Website
07 Jul 2012
Bio 2012 - Building a Diagnostics Franchise
27 Jun 2012
Commercial Launch of CUP Test
22 Jun 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
12 Jun 2012
Circadian makes $1M Share Placement
12 Jun 2012
Reinstatement to Official Quotation
07 Jun 2012
Suspension Confirm
07 Jun 2012
Suspension Request
05 Jun 2012
Request for Trading Halt
01 Jun 2012
Updated Corporate Presentation
27 Apr 2012
Notice of Ceasing to be a Substantial Holder
02 Apr 2012
Change of Director’s Interest Notice
29 Mar 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
15 Mar 2012
Analyst Investment Research Report Available on Circadian Website
09 Mar 2012
Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test
09 Mar 2012
Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of Unknown Primary
20 Feb 2012
Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook
16 Feb 2012
Half-Year Financial Report & Operational Achievements
30 Jan 2012
VGX-100 identified as potential new therapy for improving corneal graft survival
12 Jan 2012
CEO Presentation at Biotech Showcase San Francisco
09 Jan 2012
Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients
21 Dec 2011
Change of Director’s Interest Notice
19 Dec 2011
Finance News Network Interview with CEO Available on Circadian Website
13 Dec 2011
Change of Director’s Interest Notice
25 Nov 2011
Final Director’s Interest Notice
24 Nov 2011
Results of Annual General Meeting 24 November 2011
24 Nov 2011
Annual General Meeting Presentation 24 November 2011
24 Nov 2011
Annual General Meeting Presentation 24 November 2011
24 Nov 2011
Chairman's Address to Annual General Meeting 24 November 2011
15 Nov 2011
Open Briefing with CEO & MD Robert Klupacs: CEO on IND status for VGX-100
31 Oct 2011
Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors
25 Oct 2011
Change of Director's Interest Notice
24 Oct 2011
Notice of Annual General Meeting and Explanatory Memorandum
20 Oct 2011
Change of Director's Interest Notice
18 Oct 2011
Final Director's Interest Notice
11 Oct 2011
Analyst Investment Research Reports Available on Circadian Website
11 Oct 2011
Biopartnering Europe Presentation
10 Oct 2011
Healthscope commences clinical validation study of Circadian's Cancer Diagnostic
03 Oct 2011
Retirements from Circadian Board of Directors
30 Sep 2011
Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors
15 Sep 2011
Open Briefing with CEO & MD Robert Klupacs: FY12 Outlook and VGX-100 Progress
13 Sep 2011
VGX-100 identified as potential new therapy for Dry Eye Disease
12 Sep 2011
Circadian makes key appointment in clinical trials management
11 Sep 2011
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling
09 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Circadian Corporate Presentation - Septemeber 2011
06 Sep 2011
Change of Director's Interest Notice
31 Aug 2011
Change in Substantial Holding for Optiscan Imaging Limited - Update
31 Aug 2011
Change of Director's Interest Notice
30 Aug 2011
Change of Director's Interest Notice
24 Aug 2011
Preliminary Final Report Appendix 4E Financial Year Ended 30 June 2011
25 Jul 2011
Change of Director's Interest Notice
18 Jul 2011
Change of Directors Interest Notice
14 Jul 2011
Open Briefing with CEO & MD Robert Klupacs
16 Jun 2011
Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications
16 Jun 2011
Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications
14 Jun 2011
Circadian launches Level 1 ADR program and OTCQX Quotation in US
10 Jun 2011
Substantial Holding Notice for Antisense Therapeutics Limited
07 Jun 2011
VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients
07 Jun 2011
VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients
30 May 2011
Analyst Investment Research Reports Available on Circadian Website
18 Apr 2011
Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation
Read More
07 Apr 2011
Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5
06 Apr 2011
Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer
06 Apr 2011
Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody IMC-3C5
02 Apr 2011
The novel therapeutic monoclonal antibody VGX-100 neutralises VEGF-C and inhibits tumor growth and metastasis in subcutaneous and orthotopic models of human cancer
22 Mar 2011
New issue announcement, application for quotation of additional securities and agreement
15 Feb 2011
31 December 2010 Half-Year Financial Report & Operational Achievements
14 Feb 2011
Finance News Network Interview with Circadian CEO Robert Klupacs
02 Feb 2011
Circadian Launches First Diagnostic for LAM Lung Disease with U.S. Partner
17 Jan 2011
VEGF-D Licence Agreement Open Briefing
13 Jan 2011
Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual Property Estate
11 Jan 2011
2011 Biotech Showcase
16 Dec 2010
Securities Trading Policy
15 Dec 2010
Substantial Holding Notice for Antisense Therapeutics Limited
19 Nov 2010
Change of Directors Interest Notice
18 Nov 2010
Open Briefing - VEGF Inhibitor Technology Patents
18 Nov 2010
Circadian Technologies Limited Sale of Unmarketable Parcels Complete
11 Nov 2010
2010 AGM Managing Director's Presentation
11 Nov 2010
Results of Annual General Meeting 11 November 2010
Read More
10 Nov 2010
Major US and European Patents Granted to Circadian
14 Oct 2010
Open Briefing - CEO on FY11 LAM Diagnostic Partnership
11 Oct 2010
2010 Annual Report
11 Oct 2010
Notice of Annual General Meeting and Explanatory Memorandum
05 Oct 2010
Finance News Network Video Interview with CEO (CIR)
30 Sep 2010
Circadian partners with Cincinnati Childrens Hospital in U.S. to develop blood test diagnostic for potentially fatal lung disease
17 Sep 2010
Circadian Technologies Limited to Offer Shareholder Sale Facility for Unmarketable Parcels
09 Sep 2010
Open Briefing - CEO on FY11 Outlook and Strategic Focus
06 Sep 2010
Circadian granted key strategic VEGF-D patent in USA for diagnostic applications
25 Aug 2010
Change of Directors Interest Notice
20 Aug 2010
Preliminary Final Report (Appendix 4E) Financial Year Ended 30 June 2010
18 Aug 2010
Notice of Change of Interests of Substantial Holder
18 Aug 2010
Notice of Change of Interests of Substantial Holder
16 Aug 2010
Details of the issue or offer of securities
16 Aug 2010
New issue announcement, application for quotation of additional securities and agreement
03 Aug 2010
Australian Microcap Investment Conference Presentation
30 Jul 2010
Shares to be released from escrow
28 Jun 2010
Corporate Presentation
14 May 2010
Change of Directors Interest Notice
13 May 2010
Ms Susan Madden appointed Company Secretary of Circadian
13 May 2010
Change of Directors Interest Notice
13 May 2010
Change of Directors Interest Notice
11 May 2010
Change of Directors Interest Notice
04 May 2010
VGX-100 Inhibits Tumour Growth - Open Briefing with CEO & MD Robert Klupacs
30 Apr 2010
Change of Directors Interest Notice
17 Apr 2010
VGX-100, a novel therapeutic monoclonal antibody targeting VEGF-C that inhibits tumor growth
15 Apr 2010
Ms Natalie Korchev to resign as CFO and Company Secretary
15 Apr 2010
VGX-100 significantly inhibits tumour growth in animal cancer models
06 Apr 2010
Circadian Newsletter - April 2010
26 Mar 2010
Change in substantial holding
24 Mar 2010
Current Corporate Presentation
24 Mar 2010
Corporate Presentation
17 Feb 2010
Half Year Results and Operational Achievements
05 Feb 2010
Change in substantial holder
22 Dec 2009
Commencement of Circadian non-executive director share plan
07 Dec 2009
Circadian and CSIRO enter strategic research alliance
19 Nov 2009
2009 AGM Managing Director's Presentation
19 Nov 2009
Results of Annual General Meeting
19 Nov 2009
2009 AGM Managing Director's Presentation
10 Nov 2009
Merriman Presentation
10 Nov 2009
CIR to present at Merriman Curhan Ford's US Investor Summit
29 Oct 2009
Circadian subsidiary terminates licence to Ark Therapeutics
16 Oct 2009
Open Briefing - CEO on Manufacturing Milestone and Update
14 Oct 2009
Notice of Annual General Meeting
14 Oct 2009
2009 Annual Report
13 Oct 2009
Manuafacturing milestone achieved for cancer drug candidate VGX-300
14 Sep 2009
Change of date for Circadian's 2009 AGM
09 Sep 2009
Change of Director's Interest Notice - Robert Klupacs
08 Sep 2009
Change in substantial holder
07 Sep 2009
Circadian provides PerkinElmer with worldwide rights to market research products
03 Sep 2009
Circadian Newsletter - September 2009
25 Aug 2009
Initial Director's Interest Notice - Dr Errol Malta
25 Aug 2009
Circadian granted key VEGF-C patent in Japan
20 Aug 2009
Preliminary final report
20 Aug 2009
Dr Errol Malta appointed non-executive director
30 Jul 2009
Shares to be released from escrow
09 Jul 2009
Corporate Presentation
09 Jul 2009
Corporate Presentation
30 Jun 2009
Appendix 3B - Employee incentive
18 Jun 2009
Circadian granted key strategic VEGF-D patent in Europe for angiogenic applications
03 Jun 2009
Circadian sponsors international conference on angiogenesis research
22 May 2009
Circadian licensee Ark Therapeutics announces Trinam phase III study enrols first patient
19 May 2009
Open Briefing - CEO on Recent Achievements
13 May 2009
FINSIA Presentation
13 May 2009
FINSIA presentation - "The Survivors: strong business and balance sheet"
06 May 2009
Circadian Scientific Advisory Board Chairman, Prof. Kari Alitalo, wins prestigious award for biomedical research
24 Apr 2009
BioMelbourne Network Presentation
24 Apr 2009
Change of Director's Interest Notice - Dominique Fisher
24 Apr 2009
BioMelbourne Network presentation - Transformation of Circadian
22 Apr 2009
Circadian partner ImClone Systems demonstrates VEGFR-3 antibody improves anti-tumour effects of chemotherapy in mouse tumour models
02 Apr 2009
Circadian Newsletter - April 2009
26 Mar 2009
Corporate Presentation
26 Mar 2009
Corporate Presentation
02 Mar 2009
Open Briefing on Cancer Diagnostic Commercialisation
25 Feb 2009
Circadian and Healthscope to commercialise Peter Mac Cancer Diagnostic
09 Feb 2009
Half-Year Results & Operational Achievements
22 Jan 2009
Open Briefing - CEO on Trinam Phase III Trial
09 Jan 2009
Ark Therapeutics receives clearance to commence Phase 3 trial of Trinam
14 Nov 2008
Managing Director's AGM Presentation
21 Oct 2008
Corporate Presentation
16 Oct 2008
Wilson HTM Life Sciences Showcase
25 Jun 2008
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
04 Jan 2008
Change of Directors Interest Notice
04 Jan 2008
Change of Directors Interest Notice
02 Jan 2008
Change of Director's Interest Notice
11 Dec 2007
Change in Substantial Holding
03 Dec 2007
Leon Serry, Managing Director of Circadian, announces retirement effective 1 March 2008, Robert Klupacs appointed CEO elect
25 Oct 2007
Results of AGM
25 Oct 2007
Final director's interest notice
25 Oct 2007
Resignation as a director - Graeme Kaufman
24 Oct 2007
Presentations to AGM
21 Sep 2007
Annual report and notice of AGM
13 Sep 2007
Change of registered office address
21 Aug 2007
Becoming a substantial holder
14 Aug 2007
Preliminary final report
31 Jul 2007
Change in substantial holding
29 Jun 2007
Vegenics & Sienagen to exploit VEGF-D in bone disease
18 Jun 2007
Vegenics further extends VEGF-C intellectual property
23 May 2007
Vegenics licensee announces early trial clearance
09 May 2007
Ceasing to be a substantial holder for AVX
30 Apr 2007
Circadian to present at US investor forums
27 Apr 2007
Notice of initial substantial holder - AVX
18 Apr 2007
Change in substantial holding for OIL
13 Apr 2007
Licences novated to Vegenics
02 Apr 2007
Vegenics completes capital raising
29 Mar 2007
Change in substantial holding for AVX
29 Mar 2007
Ceasing to be a substantial holder for AVX
22 Mar 2007
Appendix 3B Employee incentive
27 Feb 2007
Antibody development collaboration with EvoGenix
13 Feb 2007
Half yearly report and accounts
13 Feb 2007
Appendix 3B Employee incentive
05 Feb 2007
Change in substantial holding for AVX
31 Jan 2007
Results of General Meeting
24 Jan 2007
Change in substantial holding for AVX
19 Jan 2007
Additional investment in Vegenics
19 Jan 2007
ASX listed shareholdings update
12 Jan 2007
Change in substantial holding for AVX
12 Jan 2007
Change in substantial holding for MBP
11 Jan 2007
Becoming a substantial holder
28 Dec 2006
Notice of General Meeting
01 Dec 2006
ASX listed shareholdings update
30 Nov 2006
Change in substantial holding for MBP
21 Nov 2006
Appendix 3Y Change of director's interest
15 Nov 2006
Change in substantial holding for ANP
13 Nov 2006
Change in substantial holding for AVX
27 Oct 2006
Results of AGM
27 Oct 2006
Executive long-term incentives
26 Oct 2006
Presentations to AGM
25 Oct 2006
Amended change in substantial holding for ANP
11 Oct 2006
Award of grant for conotoxin development
22 Sep 2006
Annual report and notice of AGM
21 Sep 2006
Additional investment in Vegenics
28 Aug 2006
Preliminary final report
22 Aug 2006
Vegenics announces agreement with CoGenesys
17 Jul 2006
Resume trading
10 Jul 2006
Grant for cancer vaccine development
30 Jun 2006
Completion of due diligence on Ludwig project
15 Jun 2006
Extension to collaboration with University of Sydney
17 May 2006
Change in substantial holding for AVX
02 May 2006
Presentation on Vegenics cancer project
01 May 2006
Major cancer development agreement
11 Apr 2006
Change in substantial holding for ANP
31 Mar 2006
ASX listed shareholdings update
31 Mar 2006
New research project
10 Feb 2006
Half yearly report and accounts
01 Aug 2005
Inhibition of Lymphogenous Metastasis Using Adeno-Associated Virus-Mediated Gene Transfer of a Soluble VEGFR-3 Decoy Receptor
01 Feb 2005
Half yearly report and accounts
14 Jan 2004
Appendix 3Y Change of director's interest
29 Jan 2003
Appendix 4B Half yearly report and review of operations
05 Jun 2002
Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling
04 Jan 2002
Initial director's interest notice x 5
30 Jan 2001
Appendix 4B Half yearly report and review of operations
01 Jan 1998
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
